Do you know about the THIRD type of autoimmune thyroid disease?
Atrophic thyroiditis may coexist with Hashimoto’s and can occur in people with Graves’ disease.
Atrophic Thyroiditis is an extreme form of primary hypothyroidism in which the thyroid gland is severely atrophied (shrunken, shrivelled) by antibody attack.
In some estimates, approximately 10% of Hashimoto’s patients carry the blocking antibodies associated with Atrophic Thyroiditis (AT) (Fröhlich & Wahl, 2017). See the statistics of how many people are affected by this form of thyroid autoimmunity in “Overlooked: How many Hashimoto’s patients with TSH-Receptor antibodies?“
But Atrophic Thyroiditis is not simply a subtype of Hashimoto’s.
Atrophic Thyroiditis is caused by a different set of antibodies than Hashimoto’s and Graves, but it is genetically and immunologically related to Graves disease, as seen in this diagram by Fountoulakis and Tsatsoulis, 2004, which I’ve color-coded and illustrated.
Paradoxically, it’s more related to Graves’ disease, even though Graves’ disease causes the opposite clinical presentation, hyperthyroidism.
As I explain in this article, many myths and general ignorance exists regarding this form of thyroid disease because thyroid autoimmunity is not as simple as it seems.
Summary: Hashimoto’s versus Atrophic thyroiditis
The first place to start learning is to distinguish Hashimoto’s from Atrophic Thyroiditis, so here is the contrast in a nutshell.
Hashimoto’s is caused by a combination of thyroid peroxidase antibodies (TPOab), inflammation, and other immune system variables (Fröhlich & Wahl, 2017).
Atrophic Thyroiditis (AT), however, has a different cause and prognosis than Hashimoto’s:
- Atrophy involves TSH-receptor blocking antibodies (TBAb). Confusion has arisen regarding TBAb as the essential contributing factor because the antibody can completely disappear after thyroid atrophy, and some people with the antibody do not suffer atrophy but enjoy a complete remission. Clearly, TBAb is not the sole cause, but it is so frequently found in people with thyroid atrophy that it is far more than a coincidence (Fröhlich & Wahl, 2017).
- AT is not “end-stage [Hashimoto’s] thyroiditis,” but that’s a common medical myth. While the vast majority of Hashimoto’s patients retain normal thyroid volume into old age, severe thyroid volume loss from AT can occur at any age, even in early childhood (Jara et al, 2008).
- The time-scale of AT may be swift or intermittent. In contrast with Hashimoto’s, which can, in some cases, take decades to gradually damage the gland enough to cause hypothyroidism, AT often leads to far swifter process of thyroid gland volume loss and destruction if certain antibodies coexist in a susceptible person. Remissions may occur between successive flares of the antibody.
- AT can interfere with hormone therapy. Hashimoto’s antibodies do not appear to interfere with hypothyroid therapy, other than by causing gradual destruction of the thyroid. But during treatment with thyroid hormone, TBAb can cause wild fluctuations of TSH, FT4 and FT3 if even a small remnant of a thyroid remains. The antibody blocks TSH hormone from stimulating the thyroid to varying degrees. They will also block TSH receptors located elsewhere in the human body, but extrathyroidal effects of TBAb on bone, heart, kidney, skin, and eyes have not yet been traced back to the antibody.
- AT can affect both maternal and fetal health during pregnancy, and the TSH receptor antibodies cross the placenta. But if the fetus’s TSH receptors are blocked, they can still survive on maternal thyroid hormones. If the child does not create their own antibodies, they may have transient congenital hypothyroidism during the neonatal phase, and they can recover. (See “TBAb hypothyroidism diagnosed in a mother and baby.”)
Many of these points are elaborated below.
Myths and ignorance of atrophic thyroiditis
Despite its severity and influence on health, atrophic thyroiditis not easy to diagnose.
This is because of widespread medical amnesia and myths, the absence of goiter, the frequency of antibody fluctuations, and problems with testing technologies and test ordering practices.
The current level of ignorance and the widespread myths about this thyroid disease entity is astounding.
Atrophic thyroiditis used to be better known more than 20 years ago when hypothyroidism was classified into either of two presentations based on there being thyroid swelling (goiter) or not, prior to thyroid hormone treatment:
- atrophic (or non-goitrous)
- vs. goitrous (Hashimoto’s) (See Bogner et al, 1992).
Most of the science on thyroid atrophy is buried in archives. I’ve discovered more than 100 articles on thyroid gland atrophy going back to the 1800s, and every decade there appear new publications on it. But scientists tend to review only the most recent 10 years of research. (See the bibliography I shared back in early 2019 when I first published this article).
This common practice of looking only at recent publications causes medical and scientific amnesia.
Today, most doctors and patients have never heard about Atrophic Thyroiditis (AT). That’s because it’s not usually taught in medical school anymore, and most thyroid blogs, books, and websites don’t mention it.
One reason why AT has been overlooked is that it simplifies diagnosis to pretend that it does not exist.
Real thyroid autoimmunity is not simple, but a complex overlapping web of antibodies and clinical presentations. The blocking and cleavage antibodies can occur in people who also have Hashimoto’s or Graves’ disease. The full spectrum of thyroid autoimmunity involves overlapping antibodies in some patients.
The drive to oversimplify thyroid diagnosis has been going on for decades. Some thyroid scientists and textbook writers appear to find the scientific fact of complex thyroid “multi-autoimmunity” too confusing for their students or readers. The large number of people with autoimmune hypothyroidism makes it too tempting to simplify the autoimmune hypothyroid category and treat it as if it’s homogeneous.
As a result of these myths and lack of knowledge, many people with Atrophic Thyroiditis (such as myself) have been misclassified as Hashimoto’s thyroiditis.
This mistake is based on the false assumption that ALL autoimmune hypothyroidism is Hashimoto’s.
Most forms of autoimmune thyroid disease are associated with the thyroid peroxidase (TPO) antibody known to be involved in Hashimoto’s.
Even some Graves’ disease patients are positive for TPOab. Therefore, many diagnostic algorithms stop after measuring TPOAb, and some stop after measuring both TPOAb and thyroglobulin (TG) antibodies.
However, neither thyroid gland atrophy nor TSH-blocking antibody activity require the presence of the TPO antibody or TG antibody.
The TPO antibody is in fact incapable of causing thyroid gland atrophy (Fröhlich & Wahl, 2017). Instead, TPO antibody is implicated in lymphocytic infiltration of thyroid cells without thyroid volume loss. Only in cases where a person has both Hashimoto’s AND TSH receptor blocking / cleavage antibodies will you find thyroid atrophy occur in a Hashimoto’s patient.
- How can it be the “end stage” of Hashimoto’s if it occurs even in a five-year-old child? (Inamo et al, 2011)
Therefore, it is false to claim that an atrophied thyroid is “end-stage” Hashimoto’s !
This myth of “end-stage Hashimoto’s” is still perpetuated by research publications. Authors who claim this sometimes perform incomplete literature reviews that omit crucial Japanese sources (although they were published in English). Others don’t fact check their sources’ claims. Some are simply ignorant. They don’t understand the various subtypes and mechanisms of the TSH receptor antibody.
Some patients are even left as unclassified cases of hypothyroidism of unknown, antibody-negative or “idiopathic” cause just because the Hashimoto’s TPO antibodies are absent or (as in my case) present but not elevated.
A final barrier is antibody testing. If you want to test for the TSH receptor blocking antibodies, good luck!
Some Graves’ hyperthyroidism tests available at laboratories, such as the TSI test, do not focus on the blocking antibody but rather the stimulating antibody alone, and they are usually only ordered if a person is hyperthyroid.
Some TRAb antibody tests can measure both blocking and stimulating antibodies, but you have to test at the right time. You have to catch the antibody in the midst of a flare. Both Graves’ stimulating antibodies and AT blocking antibodies are known to completely disappear (go into remission) and to occasionally return (relapse).
Therefore, testing for the blocking antibody is not a reliable way to diagnose Atrophic Thyroiditis due to the high likelihood of a false negative during remission. (See the section below for practical tips on AT signs and diagnosis).
What causes Atrophic Thyroiditis?
Atrophic thyroiditis is defined in various ways, but in this article, I consider atrophic thyroiditis as permanent, autoimmune-caused severe thyroid gland atrophy necessitating lifelong thyroid hormone replacement.
Another phenomenon caused by the same TBAb antibody is transient autoimmune “blocking hypothyroidism,” that need not always cause a lifelong disabling state of thyroid gland atrophy. See Tagami et al, 2019.
Atrophic Thyroiditis is a HYPOthyroid form of Graves’ disease. Jara, et al, 2008, explains that Atrophic Thyroiditis patients usually have a Graves’ disease genetic profile, which is quite distinct genetically from Hashimoto’s.
- The normal form of Graves’ HYPERthyroidism is caused by TSH-Receptor *stimulating* antibodies that overstimulate the thyroid gland to produce hormone, even in the absence of TSH.
- But Atrophic Thyroiditis is associated with the presence of TSH-Receptor *blocking* antibodies that cause HYPOthyroidism.
The blocking antibody prevents TSH from stimulating TSH receptors in the thyroid gland and other tissues where the receptor is expressed. Therefore, even in patients with extremely high TSH levels over 100 can have no TSH stimulation of their thyroid gland when the antibody is strong enough to block the receptors.
- As demonstration that the blocking antibody is a Graves’ disease-associated antibody, according to Fröhlich & Wahl, 2017, “Thyroid Autoimmunity,” blocking anti-TSH-Receptor antibodies occur in 25–75% of Graves’ Disease patients.
It is now known that *cleavage* (formerly called “neutral”) TSH-receptor antibodies that can cause thyroid cell apoptosis in the absence of the stimulating antibody, and that the presence of the stimulating antibody protects the gland from apoptosis (Morshed et al, 2013, 2015).
- Like the blocking antibody, the cleavage antibody is also a Graves’ disease-associated antibody. Morshed et al, 2010, mentioned that 59% of Graves patients in a study had the neutral/cleavage TSH-receptor antibodies in circulation.
The suppression of TSH hormone in circulation cannot cause thyroid gland atrophy. This is because the healthy TSH receptor has the ability to signal when empty, and it signals independently of TSH hormone in blood. This is known as “constitutive,” “basal,” or “ligand-independent” TSH receptor activity (Furmaniak et al, 2015). As demonstration of this principle,
- In patients with pituitary dysfunction (central hypothyroidsm), many of whom cannot secrete any TSH during adequate thyroid treatment, thyroid gland volume and function is usually maintained despite TSH deficiency (Persani et al, 2019).
The TBAb antibody is the only known natural substance known to scientists that can stop the “constitutive” signal of the TSH receptor. The TBAbs harvested from a female with autoimmune thyroid disease, labeled “5C9” (Sanders et al, 2010), have become the basis of the development of a synthetic drug that one day could treat thyroid diseases worsened by TSHR signaling, like some thyroid cancers.
But the TBAb antibody on the thyroid does not always lead to atrophy:
- Patients who experience severe TSH-blocking hypothyroidism caused by the blocking antibody can experience severe, yet transient, hypothyroidism. But they can experience full remission because the blocking antibody alone does not always result in disabling thyroid atrophy.
- After the blocking antibody disappears from blood, a person can revert to a state that requires no thyroid therapy if enough thyroid tissue remains to support normal TSH-driven thyroid function. (Takasu et al, 2000)
Therefore, current science points to the TBAb in addition to other factors as the likely cause of thyroid gland atrophy (severe shrinkage), just as Hashimoto’s is caused by TPOab in addition to other factors.
AT patients with incomplete atrophy can flip between hypo and hyper status
You may often hear the mantra that “thyroid antibodies don’t affect treatment,” but that’s false with regard to Graves’ disease antibodies, and it’s also false with regard to Atrophic Thyroiditis antibodies.
The antibodies that are part of this thyroid disease can significantly interfere with lifelong thyroid therapy, if or when the antibody persists, or if the antibody attack returns long after thyroid atrophy has decimated the thyroid gland.
According to Takasu et al, 2012, a small percentage of hypothyroid patients with the blocking antibody, as well as Graves’ disease patients, can flip between hypothyroid, hyperthyroid and euthyroid status over many years, depending on whether the blocking antibody predominates over the stimulating antibody, or whether the two antibodies are in balance with each other, and whether there is enough thyroid tissue to overstimulate.
TSHR antibody levels can fluctuate wildly and can also completely disappear or resurface over time.
A real example — My thyroid and failed therapy
A normal female gland is about 12-15 mL volume. My gland is 0.5 mL, a size that is found in less than 2% of autoimmune thyroid patients, according to Carle et al, 2009.
I was without hypothyroid symptoms until my late 20s. In my early 30s I presented with a TSH over 150 without any goiter, which should have been a clear diagnostic sign to my doctor.
Because of my lack of goiter, my severe hypothyroidism went undiagnosed until I was in a severe state of mental and physical distress that interfered with daily life and work. I misattributed my health problems to my other autoimmune disease (ankylosing spondylitis). Finally, after looking up my many symptoms online, I was the one who asked for a TSH test.
Because the TSH was so clearly elevated, I was put on therapy with no further antibody tests, and no ultrasound was ordered to explain the lack of goiter which is usually present with an elevated TSH.
In my final 3 years of therapy on Synthroid, I had a TSH receptor blocking antibody attack. Previously, records show I had a TSH that ranged from low-normal to almost suppressed by a FT4 at top of reference range and a FT3 level in the lower half of reference.
When the antibody attack arrived (or returned after many years), after a small dose reduction, my TSH suddenly rose to 18.8 mU/L while my FT4 was still in the upper part of reference. I continued to have a high and variable TSH level despite a high-normal FT4. Meanwhile, the Total and Free T3 level remained almost flatlined below reference range over three years and many thyroid tests.
T4 monotherapy finally became unsustainable after I fell into a severe health crisis for three months including random daily and nightly chest pain and tachycardia that triggered a numb or weak arm, legs, or severe lightheadedness. Walking, standing, and normal cognitive tasks became difficult. T3 levels fell even lower. Reverse T3 elevated far above reference, demonstrating the presence of a severe yet undiagnosed illness. Reducing T4 dose offered temporary relief from chest pain but worsened the hypothyroidism. Several attempts to return the T4 dose back to normal levels ended in severe pain and hospital emergency visits.
An ultrasound was finally ordered and revealed the atrophied thyroid gland. A TRAb antibody test completed in Alberta was negative, but a positive result was unnecessary in light of the clear ultrasound, the history of elevated TSH on diagnosis without goiter, and the recent laboratory history.
Transition to therapy with T3 hormone finally resolved the health crisis.
How the antibody warps TSH-FT4-FT3 relationships
What I experienced is a fluctuating pattern seen in others with active blocking antibodies during thyroid therapy (Tagami et al, 2019).
The loss of normal T4 feedback on TSH happens partly because the antibody blocks the ultrashort feedback loop at the pituitary gland. The “ultrashort feedback loop” has also been called the “Brokken-Prummel-Wiersinga” feedback loop after the team that published a few articles about it in the early 2000s. This pituitary TSH feedback loop has been more extensively studied in hyperthyroid Graves’ disease, but the inverse happens at the same receptor in patients with blocking antibodies.
As with cases of fluctuating Graves’ disease during treatment, as the antibody varies, TSH can be variable, unrelated to FT4 and FT3 levels, fluctuating mainly with the antibody level (Alzahrani et al, 2005). TSH becomes a distraction, not a useful measure of treatment effectiveness.
The TSH receptor blocking antibody may even function as an “inverse agonist” of TSH receptor signaling (McLachlan & Rapoport, 2013). The baseline TSH-receptor signaling could be cut off during a severe blocking antibody attack, and high levels of circulating TSH in blood would not signal at the blocked receptors in the thyroid and elsewhere across the entire body.
TSH signaling, by means elevating cAMP signaling in cells, usually upregulates Deiodinase type 2, an important deiodinase that performs T4-T3 conversion in the thyroid gland and throughout the body (Canettieri et al, 2000). Without even the basal signal produced by an empty TSH receptor, the T4-T3 conversion rate drops throughout the body, even in the pituitary and hypothalamus.
The downregulation of D2 in the pituitary could be the second reason why the TSH can become abnormally elevated in relationship to FT4 during therapy — the pituitary and hypothalamus could not convert enough T4 to T3 locally, and my circulating T3 levels were very low.
AT and Blocking hypothyroidism in pregnancy
In Graves’ disease and in Atrophic Thyroiditis, maternal TSAb (stimulating) and TBAb (blocking) antibodies can be transferred to the fetus during pregnancy.
As explained by the 2017 ATA guidelines for thyroid disease in pregnancy (Alexander et al, 2017),
“In mothers with autoimmune thyroid disease, autoantibodies to TPO, Tg, and the TSH receptor can be transmitted to the fetus. …
Whereas TPO antibodies and Tg antibodies do not significantly affect fetal or neonatal thyroid function, antibodies to the TSH receptor can stimulate or block thyroid hormonogenesis.”
Bucci et al in 2017 reviewed several studies showing how fetal and maternal health can be affected by the TSH receptor blocking antibody. In one US study of 788 neonates with congenital hypothyroidism,
“the neonatal screening program in US demonstrated potent TSHR-blocking activity in 11 cases.
The 11 babies were born to 9 mothers, all of whom were receiving thyroid replacement because of autoimmune hypothyroidism, and 3 had been treated initially for Graves’ disease.
TPO antibodies, although detectable in all mothers, did not predict the neonatal thyroid dysfunction, while the presence of TBAbs was confirmed in the serum of eight mothers: all newborns had transient congenital hypothyroidism.”
Bucci also summarized another study:
“In a large series of newborns screened for congenital hypothyroidism in Wales (375 cases identified over 966,969 infants screened), 6 (1.6%) were found to have transient congenital hypothyroidism due to maternal TBAbs.
All the mothers were hypothyroid on levothyroxine replacement therapy or were diagnosed with hypothyroidism after the reported elevation of TSH in their infants.”
Unfortunately, in both cases, the low incidence rates are biased by the fact that the case-finding was done as part of screening for congenital hypothyroidism or high TSH in the child after its birth. Even Bucci’s article examines the TBAb antibody within the context of screening for Graves disease during pregnancy.
But the danger to the fetus is extreme. It is possible that the transfer of blocking antibodies to the fetus can occur before a mother’s diagnosis and treatment. Atrophic Thyroiditis and Blocking hypothyroidism are often not diagnosed early enough because of a lack of goiter as TSH elevates. The symptoms of hypothyroidism may be misattributed to the pregnancy itself. Very severe intellectual disability can occur in a fetus who is hypothyroid during gestation because of TBAb antibodies, since their hypothyroidism may be deep and prolonged even past the first trimester. The ATA guidelines give this caution:
“Affected infants may have significantly impaired cognitive outcomes despite early and adequate postnatal treatment if maternal hypothyroidism was present and untreated during gestation.”(Alexander et al, 2017)
The low incidence rates of TBAb, partly a result of medical ignorance, make it unlikely that screening hypothyroid pregnant women for TBAb antibodies will occur anytime soon.
Therefore, the doctor or patient need to be aware of this diagnosis and its risks during pregnancy.
Common signs and diagnosis
Jara et al, offered a diagnostic pathway in 2008, in a chapter titled “Atrophic Thyroiditis”:
“we propose the following bases for AT diagnosis:
1. Clinic[al] or subclinic[al] hypothyroidism: Clinical picture of overt hypothyroidism or increase of TSH and TRH values without symptoms.
2. Positive thyroid autoantibodies: Positive thyroid stimulation blocking antibodies (TRBAb).
3. Thyroid ultrasonographic characteristic: Abnormal thyroid echographic pattern characterized by diffuse low thyroid echogenicity associated with a reduced
Criterion 1, Clinical picture. The high TSH and absence of goiter is significant in diagnosis. In my review of the literature, I see that a very high TSH (over 80 mU/L, often over 100 mU/L) at diagnosis, prior to treatment, with no goiter (no thyroid swelling) is a common finding in studies of Atrophic Thyroiditis.
However, the “clinical picture” is varied and involves more than high TSH and overt hypothyroid symptoms. Did you notice that Jara said “or increase of TSH and TRH values without symptoms?”
Are you confused? So are doctors.
That’s because the progress of AT sometimes involves fluctuations and even a tug-of-war between TBAb and Graves’ stimulating antibodies (TSAb) that might result in temporary euthyroidism based on a fragment of remaining thyroid tissue that is hyperstimulated.
The scientific literature also gives case studies with examples of the thyroid hormone fluctuations and TSH/T4 inconsistencies that occur in people who experience remissions and relapses of the blocking and/or stimulating TSH receptor antibody. See Fan et al, 2014, and the examples on page 2 of my article “Remissions and fluctuations in autoimmune thyroid disease: TRAb.”
However, Criterion #2, the antibody test, is difficult. as explained below, and TRH hormone from the hypothalamus is not tested anymore.
The best antibody test is (or was) the old TBII test — Thyrotropin-Binding Inhibitory Immunoglobulin (Khoo et al, 1999), even though the test did not reveal the blocking antibody alone. TBII tests measure both stimulating and blocking TSHR antibodies and add them together to yield a single number. The blocking activity of the antibodies can be interpreted in the context of thyroid hormone and TSH laboratory results.
Unfortunately, the old technology TBII test is being replaced by newer TRAb (thyroid receptor antibody) tests. Some of these “third generation” TRAb tests falsely claim to offer exactly what the TBII test used to provide (Ehlers et al, 2019). But if there are no scientific articles that prove that they detect the blocking antibody, how can we trust them?
It seems that most of these test developers have decided that the hypothyroid form of the TRAb antibody is not important to diagnose, from a test marketing perspective. Some of them simply measure the net difference between stimulating and blocking, giving a number only for the net stimulating effect (McLachlan & Rapoport, 2013).
Criterion #3, a thyroid ultrasound, is important, since gland atrophy remains even after the antibody has disappeared. “Reduced thyroid volume” is relative, so it needs to be assessed by sex (thyroids are smaller in women) and body surface area. Glands will show abnormal shrinkage in relationship to the person’s sex and body surface area, and sometimes an abnormal pattern of shrinkage in which the lobe that is usually larger in populations is smaller in the individual. (Vitti et al, 1994; Carle et al, 2009; Turicos et al, 2015).
Spread the knowledge
With so much at stake for the people who have Atrophic Thyroiditis, we ought to do our part in spreading the knowledge among patients and doctors.
“The prevalence and functional significance of TSHR blocking autoantibodies (TBAb) in autoimmune hypothyroidism has been less well investigated compared to TSHR stimulating Ab.
There is an increasing body of data, however, that demonstrate the clinical utility and relevance of TBAb, and thus the importance of TBAb bioassays, in the diagnosis and management of patients with AITD.”
For doctors and scientists interested in an introduction to the newest research, I highly recommend the article “Thyrotropin Receptor Blocking Antibodies” by Diana et al, 2018.
As further explanation, I recommend McLachlan & Rapoport’s article, alongside Takasu et al’s 2012 study of patients. Jara et al’s article is also very good (2008).
Read more recent articles that cover the TSH-receptor blocking antibody and Atrophic Thyroiditis:
- The Spectrum of Thyroid Autoimmunity
- Remissions and fluctuations in autoimmune thyroid disease: TRAb
- Infographics for Antibody testing
- Overlooked: How many Hashimoto’s patients with TSH-Receptor antibodies?
Click to reveal reference list
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., Peeters, R. P., & Sullivan, S. (2017). 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid: Official Journal of the American Thyroid Association, 27(3), 315–389. https://doi.org/10.1089/thy.2016.0457
Alzahrani, A. S., Aldasouqi, S., Abdel Salam, S., & Sultan, A. (2005). Autoimmune Thyroid Disease with Fluctuating Thyroid Function. PLoS Medicine, 2(5). https://doi.org/10.1371/journal.pmed.0020089
Bucci, I., Giuliani, C., & Napolitano, G. (2017). Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance. Frontiers in Endocrinology, 8. https://doi.org/10.3389/fendo.2017.00137
Canettieri, G., Celi, F. S., Baccheschi, G., Salvatori, L., Andreoli, M., & Centanni, M. (2000). Isolation of human type 2 deiodinase gene promoter and characterization of a functional cyclic adenosine monophosphate response element. Endocrinology, 141(5), 1804–1813. https://doi.org/10.1210/endo.141.5.7471
Carlé, A., Pedersen, I. B., Knudsen, N., Perrild, H., Ovesen, L., Jørgensen, T., & Laurberg, P. (2009). Thyroid Volume in Hypothyroidism due to Autoimmune Disease Follows a Unimodal Distribution: Evidence against Primary Thyroid Atrophy and Autoimmune Thyroiditis Being Distinct Diseases. The Journal of Clinical Endocrinology & Metabolism, 94(3), 833–839. https://doi.org/10.1210/jc.2008-1370
Ehlers, M., Schott, M., & Allelein, S. (2019). Graves’ disease in clinical perspective. Frontiers in Bioscience (Landmark Edition), 24, 35–47. http://www.bioscience.org/2019/v24/af/4708/fulltext.htm
Fan, W., Tandon, P., & Krishnamurthy, M. (2014). Oscillating hypothyroidism and hyperthyroidism – a case-based review. Journal of Community Hospital Internal Medicine Perspectives, 4(5). https://doi.org/10.3402/jchimp.v4.25734
Fountoulakis, S., & Tsatsoulis, A. (2004). On the pathogenesis of autoimmune thyroid disease: A unifying hypothesis. Clinical Endocrinology, 60(4), 397–409. https://doi.org/10.1046/j.1365-2265.2004.01978.x
Fröhlich, E., & Wahl, R. (2017). Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. Frontiers in Immunology, 8. https://doi.org/10.3389/fimmu.2017.00521
Furmaniak, J., Sanders, J., Núñez Miguel, R., & Rees Smith, B. (2015). Mechanisms of Action of TSHR Autoantibodies. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 47(10), 735–752. https://doi.org/10.1055/s-0035-1559648
Inamo, Y. (2011). A 5-year-old boy with atrophic autoimmune thyroiditis caused by thyroid-stimulation blocking antibodies. Journal of Pediatric Endocrinology & Metabolism: JPEM, 24(7–8), 591–594. https://pubmed.ncbi.nlm.nih.gov/21932608/
Jara, L. J., Vera-Lastra, O., & Medina, G. (2008). Atrophic Thyroiditis. In Diagnostic Criteria in Autoimmune Diseases (pp. 221–225). Humana Press. https://doi.org/10.1007/978-1-60327-285-8_42
Khoo, D. H. C., Eng, P. H. K., Ho, S. C., & Fok, A. C. K. (1999). Differences in the levels of TSH‐binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of l‐thyroxine therapy. Clinical Endocrinology, 51(1), 73–79. https://doi.org/10.1046/j.1365-2265.1999.00740.x
McLachlan, S. M., & Rapoport, B. (2013). Thyrotropin-Blocking Autoantibodies and Thyroid-Stimulating Autoantibodies: Potential Mechanisms Involved in the Pendulum Swinging from Hypothyroidism to Hyperthyroidism or Vice Versa. Thyroid, 23(1), 14–24. https://doi.org/10.1089/thy.2012.0374
Morshed, S. A., Ando, T., Latif, R., & Davies, T. F. (2010). Neutral antibodies to the TSH receptor are present in Graves’ disease and regulate selective signaling cascades. Endocrinology, 151(11), 5537–5549. https://doi.org/10.1210/en.2010-0424
Morshed, S. A., Ma, R., Latif, R., & Davies, T. F. (2013). How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis. Journal of Autoimmunity, 47. https://doi.org/10.1016/j.jaut.2013.07.009
Morshed, S. A., & Davies, T. F. (2015). Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme, 47(10), 727–734. https://doi.org/10.1055/s-0035-1559633
Persani, L., Cangiano, B., & Bonomi, M. (2019). The diagnosis and management of central hypothyroidism in 2018. Endocrine Connections. https://doi.org/10.1530/EC-18-0515
Sanders, J., Miguel, R. N., Furmaniak, J., & Smith, B. R. (2010). TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Methods in Enzymology, 485, 393–420. https://doi.org/10.1016/B978-0-12-381296-4.00022-1
Tagami, T., Hiroshima-Hamanaka, K., Umakoshi, H., Tsuiki-Naruse, M., Kusakabe, T., Satoh-Asahara, N., Shimatsu, A., & Moriyama, K. (2019). Experimental Reproduction of Dynamic Fluctuation of TSH Receptor-Binding Antibodies Between Stimulation and Inhibition. Journal of the Endocrine Society, 3(12), 2361–2373. https://doi.org/10.1210/js.2019-00012
Takasu, N., Yamashiro, K., Komiya, I., Ochi, Y., Sato, Y., & Nagata, A. (2000). Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid: Official Journal of the American Thyroid Association, 10(10), 891–896. https://doi.org/10.1089/thy.2000.10.891
Takasu, N., & Matsushita, M. (2012). Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients. Journal of Thyroid Research, 2012, 182176. https://doi.org/10.1155/2012/182176
Turcios, S., Lence-Anta, J. J., Santana, J.-L., Pereda, C. M., Velasco, M., Chappe, M., Infante, I., Bustillo, M., García, A., Clero, E., Maillard, S., Rodriguez, R., Xhaard, C., Ren, Y., Rubino, C., Ortiz, R. M., & de Vathaire, F. (2015). Thyroid Volume and Its Relation to Anthropometric Measures in a Healthy Cuban Population. European Thyroid Journal, 4(1), 55–61. https://doi.org/10.1159/000371346
Vitti, P., Lampis, M., Piga, M., Loviselli, A., Brogioni, S., Rago, T., Pinchera, A., & Martino, E. (1994). Diagnostic usefulness of thyroid ultrasonography in atrophic thyroiditis. Journal of Clinical Ultrasound: JCU, 22(6), 375–379.
32 thoughts on “The THIRD type of autoimmune thyroid disease: Atrophic Thyroiditis”
Je le suis aussi et n’était pas bien soignée depuis près de 10 ans.
I am too and have not been nicely treated since 10 years.
I am so grateful I found your site. It explains my own health. I had a partial thyroidectomy 27 years ago and was diagnosed with Hashimotos. T4 treatment for over 30 years which was OK, no major issues. Then 5 years ago my health deteriorated. Labs all over the place. Most recent endo appointment i was asked to get my medical records as he thought I must have had a full thyroidectomy as this it what my bloods suggest. I think I’m beginning to understand what’s happening. Thank you so much for the best explanations I’ve ever found. It’s going to take me a while to digest all this material but THANK YOU, THANK YOU, THANK YOU. 😊
I’m dumbfounded. All my life I’ve wondered why I don’t fit with the “normal” hypothyroidism and trying to find out why my thyroid is tiny despite clear evidence that I don’t have Hashimoto’s. Thank you, thank you, thank you
Thanks, Ida. I’m so glad you learned about your category of thyroid disease and how it’s unique.
I seriously want to cry when reading this because I have been struggling with an entire host of symptoms for 25 years or more, I am losing count as the years go on. I have had issues with severe heat intolerance, as in life changing heat intolerance, fatigue so that I feel like I am walking through knee deep mud, peripheral neuropathy (I just had surgery on my right arm for cubital and carpal tunnel), bone pain, non alcoholic fatty liver disease, dehydration, excessive thirst, excessive urination, endometriosis, super heavy periods I had a hysterectomy at 43, gall bladder had it removed in 2009, weight gain, high cholesterol, brain fog, bradycardia, I could go on and on. Finally in 2020 my new gynecologist listened to me and told my PCP I required a referral to an endocrinologist. My PCP had offered me a referral to a psychiatrist because all my symptoms were in my head. I was in the endocrinologists office for 15 minutes he looked at my labs which go back to 2006 and said I should have been diagnosed with hyperPARAthyroidism and had surgery at least back then, and of course it is not straight forward HPT with both high calcium and high PTH, I am normohormonal which means my PTH stays in the normal range while my Ca is high which is an inappropriate relationship. Yes keep reading for THYROID revelations. So I was sent for scans, I had two US (and other scans) and this is what both of my US showed in regards to my thyroid: There is diffuse mild heterogeneity of the right thyroid parenchyma. I was told this is an US diagnosis of Hashimoto (over the years I have had maybe 3 TSH tests which came back normal and those are the only thyroid tests anyone ever did). My endo did nothing else regarding my thyroid. I had a parathyroidectomy on 7/2/21 and this is where all the interesting stuff starts, this is directly from my surgical report: “Midline fascia was opened and the strap muscles were dissected off the thyroid anteriorly. We began the exploration on the left side. We dissected the strap muscles off the left thyroid. There were extensive adhesions of the strap muscles to the left thyroid lobe, obliterating the usual tissue planes and landmarks. The left thyroid was atrophic, very fibrotic and inflamed. The middle thyroid vein was ligated and divided. We placed a retraction suture in the left thyroid to help with exposure and retraction. We identified the left recurrent laryngeal nerve low in the neck, confirming it with the nerve stimulator. As we explored the left neck, mobilization of the thyroid was difficult because of its firm fibrotic nature” We dissected the strap muscles off the right thyroid. The middle thyroid vein was ligated and divided. The right recurrent laryngeal nerve was identified. Once again, the thyroid had quite a bit of fibrosis and inflammatory changes surrounding it, making it difficult to dissect away from surrounding structures.” “The patient tolerated the procedure well and all counts were correct. Please note that the patient’s operation was much more technically difficult, time consuming, and had higher potential risk associated with it than does usual parathyroidectomy. This was because of the patient’s parathyroid glands were extremely difficult to find. The patient’s thyroid was very fibrotic, inflamed, and firm making exposure and dissection more difficult. In addition, bilateral thymectomy was performed, which is not usually required for parathyroidectomy. The operation took over twice as long as it would normally take and there was increased risk of injuring parathyroid glands with temporary or permanent hypoparathyroidism, injuring both recurrent laryngeal nerves and other surrounding structures”, my surgeon ran my TSH aprx. a week and a half post surgery, it was .351. I have struggled to get any answers from ANYONE else in regards to my thyroid, my endo (now my old endo) ran TSH (3.91 with a range of .358-3.74) and FT4 (.8 with a range of .76-1.46) and TPO (.3) on 8/2/21 and TSH (2.13 same range as previous) on 9/24/21 and stated there is nothing wrong with my thyroid. I do need a re-op for my HPT as my surgery took so long he had to basically get out of my neck. I struggle to get through each and every day. There is obviously no one who has a clue about atrophic thyroiditis, but, I absolutely feel vindication reading this. I just don’t know where to go from here.
Thank you for the article. I suffer under hypothyroidism symptoms since I am 14 years old, was only “suplemented” with T4 when I was 30 years old. I am 41 now and do not loose any symptoms. When I increase it, I even could feel better for some days, even warm but it never lasts. I have an AT (3 ml) which is labeled as “hashi seronegative” or “just peoples thyroid shrinks over time”. I have none of the three antibodies. I would put myself in the category blocked receptor. I could swear I have noting in my cells. My TSH is always 0.01 under supplemention. I would have loved to fit in the this category :(((((
nice piece of information
Does anyone know where in the USA there are doctors, NOT naturopaths, who take atrophic thyroid seriously? If not, where in Canada? I have NO thyroid gland and am no longer helped by levothyroxine. Nobody takes this seriously here in CA.
I am in Maine and know exactly what you are going through, I can’t find anyone be to help me. Have you tried Dr Babak Larian? He is in CA Larianmd dot com I had a consult with him about my Hyperparathyroidism and have not spoken to him about my thyroid. The only one who has really responded to me was Dr Paul Robinson who is in the UK, he said he would help me remotely, but I need to get my Hyperparathyroidism squared away first as I have hyperplasia and am really sick from it.
I am sorry to say that I’m very confused. I was diagnosed with Hashimoto’s based on an ultrasound that produced a picture of a severely atrophied thyroid. At the time I trusted doctors 200%, so don’t know whether I was tested for antibodies as well. My TPO now is normal, my TgAb elevated. Depending on the tests done, Hashimoto’s has been denied when only TPO was tested. One endo, who seemed quite knowledgeable about thyroid issues, said a TrAb test should probably be done but then did not order it (I assume that it is discouraged like many other tests, such as vitamin D status). Can Hashimoto’s lead to an atrophied thyroid? Or is an atrophied thyroid exclusively caused by AT? My TSH used to fluctuate wildly but since being on T3/T4 combo it is consistently below the reference interval. Also, I seem to be very sensitive to even small changes in thyroid hormones, with values shooting up or down with the slightest change (don’t know whether that signifies anything). Is it possible that I have both Hashimoto’s and AT? Not that it matters to my current doctor, but I would like to know.
Thank you for your publications. I hope you can clarify things for me in this situation. Thanks for your help.
I’m Hashimoto with an athrophic thyroid. I was on high dose of synthroid for a long time before the doctor accept to test for hashimoto and find my athrophic thyroid.
My new doctor found that my first problem is pancreatic. What I understabd of the theory he had was that the long time of high dose of synthroid and the not conversion caused the athropic thyroid.
Josee, your doctors theory about high dose Synthroid and poor conversion causing atrophy is not consistent with the evidence. Here are three reasons why. 1. In the scientific literature, people have been diagnosed with thyroid gland atrophy before being placed on Synthroid.
2. Poor T4 -T3 conversion (manifested in low FT3-FT4 ratios) is seen in a significant percentage of people with total thyroidectomy, and it’s not surprising that it’s also seen in some people with severe thyroid atrophy, so maybe this is why the physician imagined that poor conversion was a cause when it is more logically the effect of lack of functional thyroid tissue.
3. Some doctors also imagine that TSH suppression by high dose T4 causes thyroid atrophy, but this doesn’t happen. People with central hypothyroidism due to pituitary dysfunction are treated with T4 to the point of TSH suppression, and if they have healthy thyroids and no autoimmune thyroid disease, their thyroids do not atrophy. Before the TSH test was refined in 1988, many hypothyroid patients and people with goiter used to be treated to TSH suppression, and there is no record of this practice causing thyroid atrophy.
My left lobe is way worse than my right lobe. I’m having a second PARAthyroidectomy on 3/2/23, they will have eyes on my thyroid once again during this next surgery. Reading about a lot of your issues, have you ever been tested for hyperPARAthyroidism? A lot of your issues including kidney, the memory issues, and pancreas are common with HPT. And doctors including endocrinologists have very little knowledge of HPT. HPT will make you feel like you have end stage dementia. I have bilateral carpal and cubital (elbow) tunnel, I have bilateral renal atrophy, chronic gastritis, my hands are a mess tendinitis and Dupytrens contracture and multiple fibrotic type growths on every knuckle..
I’m kind of in the same boat as you, I am in the US and absolutely no doctors have any knowledge of AT, I had a parathyroidectomy on 7/2/2021 and my surgery was super difficult due to the state of my thyroid during surgery Atrophic, very fibrotic with inflammatory changes. My thyroid volume was 5.6 7/22 2/23 it has now shrunk to 4.5 according to Dr Paul Robinson in the UK a thyroid volume in an adult of 5 ml or less is indicative of AT. I’m beyond frustrated the only full thyroid labs I have had have been ones I have run myself and my labs are basically normal but no doctors have ever run a full thyroid panel for me. It is beyond frustrating
And here in the US I have not found any lab that tests TBAb
Is it atrophic thyroiditis if it only affects 1 lobe? I fit the prognosis in that my TPO was high but I had no goiter. I was also functionally profoundly hypothyroid for about 12 years before testing as hypothyroid. I had a series of kidney infections and an eventual failure (going back and cross refering test results I’m sure they were caused by creatinine surges), bilateral carpal tunnel, and all the more normal symptoms of hypothryoidism.
When I finally tested as hypothyroid my TSH roose quickly. It was 9.64 on 150 mcg t4 and euthyroid at 200mcg in one test and too low in another test so they cut me back and I got sicker and sicker, lost upper body muscle to where I had to get the ipad case without the weighty pencil holder and developed head to toe arthritis severe enough to require multiple surgeries. My breathing was pretty wrecked and some other horrors tharat the time I though were extreme Hashimoto’s but in retrospect. fit undertreated hypothyroidism better. Anyway, I got sicker and sicker. I started to drop things and think one word and write another though, so maybe Hashimoto’s encephalopathy.
In other strangeness my petite thyroid was palpable interfering in my throat for a few years before I finally went completely mute. I was mute 8 months before a surgeon would do a thyroidectomy for anything but cancer. The irony thing is that in surgery they found cancer. They also found thymic tissue but I don’t think that was the interference as I don’t think that has growth spurts.
Anyway, the thyroid is out, breathing is hard multiple ways, I’m arthritic AF and I have some kind of systemic fibrosis that no doctor will listen to me discuss any more than when I said that my TSH meant squat and I needed more t4 and maybe throw me a little t3 and.
Anyway, I now manage my own supplementing because it’s safer and I have profound anger about the fact that I was dying for a time and am physically damaged because so few thyroid specialists read.
Anyway, any idea what caused all that (not the doctor part, the rest) and what to do from here? A little background: my father died from type 1 diabetes and my mom, her mom and grandfather all had thyroid cancer. It likely goes further back, but the diagnosis doesn’t.
Finally it makes sense how some 15 years ago in a single one of lab tests my TrAbs were extremely high while being subclinically hypothyroid and a “Hashimoto’s thyroid” showing after ultrasound.
I used to think for 15 years that the lab named the antibodies wrong in the report. That they meant Tg antibodies, that I couldn’t have had such elevated TrAbs as weeks later in a different lab they were normal (non-existent) again (only Tg antibodies elevated) and every lab work since showed the same: no elevated TrAbs.
I used to think it was a lab mistake, but now it all makes sense. I had had a flare.
Thank you so much!